NexGel (NexGel) ROCE % : -46.51% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexGel ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NexGel's annualized ROCE % for the quarter that ended in Mar. 2024 was -46.51%.

NexGel ROCE % Historical Data

The historical data trend for NexGel's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexGel ROCE % Chart

NexGel Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-270.46

-223.72

-30.79

-28.91

-37.54

NexGel Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-33.97	-27.66	-25.64	-60.34	-46.51

NexGel ROCE % Calculation

NexGel's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.173	/	( ( (10.357 - 0.859)	+	(9.955 - 2.549) )	/ 2 )
	=	-3.173	/	( (9.498	+	7.406)	/ 2 )
	=	-3.173	/	8.452
	=	-37.54 %

NexGel's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-3.56	/	( ( (9.955 - 2.549)	+	(10.385 - 2.483) )	/ 2 )
	=	-3.56	/	( ( 7.406	+	7.902 )	/ 2 )
	=	-3.56	/	7.654
	=	-46.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

NexGel (NAS:NXGL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NexGel ROCE % Related Terms

Thank you for viewing the detailed overview of NexGel's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NexGel (NexGel) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047

Website

https://www.nexgel.com

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing.

Executives

Steven Mark Glassman	director	99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein	director	QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Scott Robert Henry	director	34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky	director	850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Yaakov Spinrad	director	3450 OAKTON ST, SKOKIE IL 60076
Drapczuk Adam E Iii	officer: Chief Financial Officer	6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc	10 percent owner	C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
Adam R. Levy	officer: CEO and President	2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
David Ian Johnson	director, officer: Chief Executive Officer	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc.	10 percent owner	100 PINE ST., STE. 500, SAN FRANCISCO CA 94111